Risk factor
Poor trading liquidity
Moderate default risk
Average price volatility
Profitability factor
Decent price performance
Very low or no dividends
Overvalued vs peers
Risk / Profitability
Risk: Moderate
Profitability: Modest
Risk factor
Poor trading liquidity
Moderate default risk
Average price volatility
Profitability factor
Decent price performance
Very low or no dividends
Overvalued vs peers
€ 20.7
About
Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and...
About
Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the...